-
2m 51s
-
12m 11s
-
13m 49s
-
5m 53s
-
8m 4sPart 3 | Session 1 EAS 2026 Data Highlights: Emerging Evidence on Targeted Therapies
-
4m 42sPart 3 | Session 2 EAS 2026 Data Highlights: Lp(a) and Residual Risk: Entering the HORIZON Era
Dr Scott Vafai takes us through the interim results from the Heart-2 study, including the safety profile, the magnitude and durability of LDL-C reduction, and what these results could mean for the future management of patients.
This programme provides a focused spotlight on the latest developments and data presented at the European Atherosclerosis Society (EAS) Congress. Through a series of sessions, recorded at EAS and contributed by various faculty members, each offers concise analysis of late-breaking trial data, sub-analyses, and the clinical implications shaping contemporary lipid management.
Key Learning Objectives
- Identify suitable patients for ApoC-III initiation using validated scoring parameters
- Recall the most recent guidance for the use of ApoC-III inhibitor therapy
- Discuss emerging clinical evidence of TG-lowering therapies across important trial sub-populations
Target Audience
- Cardiologists
- Lipidologists
- Gastroenterologists
- Endocrinologists
- Other specialists associated with the management of familial chylomicronaemia syndrome (FCS)
More from this programme
Part 1
A Deep Dive Into the Data: Targeting ApoC-III Special Populations
The burden of hypertriglyceridemia (HTG) spans a broad and diverse patient population, from rare genetic disorders such as familial chylomicronaemia syndrome (FCS) to mixed hyperlipidaemia and familial dyslipidaemias. Current treatment strategies, including statins and fibrates, remain limited in their ability to adequately control triglyceride levels in many patients, highlighting the need for education around emerging therapeutic classes. ApoC-III–targeted therapies are demonstrating significant TG-lowering potential and are increasingly being evaluated across a wider range of patient populations, including those with FCS.
In this video, Dr Erin Michos (Johns Hopkins University School of Medicine, Baltimore, US) provides a deep dive into data presented at EAS 2026, targeting APOC-III in special populations.
This session is supported by an unrestricted educational grant from Arrowhead Pharmaceuticals.
Part 2
In Context: A Peer-To-Peer Discussion on ApoC-III in Special Populations and Other Emerging Data
The burden of hypertriglyceridemia (HTG) spans a broad and diverse patient population, from rare genetic disorders such as familial chylomicronaemia syndrome (FCS) to mixed hyperlipidaemia and familial dyslipidaemias. Current treatment strategies, including statins and fibrates, remain limited in their ability to adequately control triglyceride levels in many patients, highlighting the need for education around emerging therapeutic classes. ApoC-III–targeted therapies are demonstrating significant TG-lowering potential and are increasingly being evaluated across a wider range of patient populations, including those with FCS.
In this video, Dr Michos (Johns Hopkins University School of Medicine, Baltimore, US) is joined by Dr Christie Ballantyne (Baylor College of Medicine, Houston, US) for an in-depth discussion on real-world implications and clinical decision-making around applying emerging guidance and evidence in severe hypertriglyceridemia and FCS. They review evolving guidelines and what emerging data tells us about managing complex patient populations.
This session is supported by an unrestricted educational grant from Arrowhead Pharmaceuticals.
Part 3
EAS 2026 Data Highlights
Expert analysis of breaking congress data, highlighting key takeaways and impact on clinical practice.
Faculty Biographies
Scott Vafai
Chief Medical Officer
Dr Scott Vafai, MD is Chief Medical Officer at Verve Therapeutics. Dr Vafai is an internist based in Boston, Massachusetts. He serves as a Research Fellow in Medicine at Massachusetts General Hospital, with clinical and research expertise in endocrinology, metabolism, cardiovascular genetics, and gene-editing therapeutics. Dr Vafai has contributed to leading biomedical research focused on mitochondrial biology and precision medicine.